Skip to content
Research Article Open access CC BY 4.0

Diagnostic Performance of N Terminal-Pro Brain Natriuretic Peptide (NT-ProBNP) in the Assessment of Dyspnea in Heart Failure and Chronic Obstructive Pulmonary Disease in a Group of Patients in Sub–Saharan Africa (SSA): An Analytical Cross-Sectional Study

Vicky Ama Moor, Liliane Mfeukeu Kuate, Manuela Eko, Daryl N. Tcheutchoua, Mbono Samba, Jan Réné Nkeck, Christian Ouankou Ngongang, Virginie Poka, Batakeh Ba Agoons, Honoré Kemnang, Eric Yone Pefura, Alain Menanga

International Journal of Biochemistry Research & Review · pp. 45–51 · Published 30 Oct 2021

10.9734/ijbcrr/2021/v30i630275

Abstract

Background: Heart failure (HF) and Chronic Obstructive Pulmonary Disease (COPD) are two conditions frequently responsible of dyspnea. The clinical distinction between these two etiologies is challenging in clinical practice, particularly in developing countries where access to imagery is limited. Thus, natriopeptides, secreted during the stretching of cardiomyocytes, could be a more accessible method for the etiological diagnosis of dyspnea. Objective: The aim of this cross-sectional study was to evaluate the diagnostic performance of NT-pro BNP in the assessment of dyspnea during heart failure and COPD. Methods: The population consisted of patients with dyspnea caused by heart failure according to Framingham criteria or COPD diagnosed according to GOLD criteria. The NT-pro BNP levels and left ventricular ejection fraction was assessed. The ROC curve and the Youden index was used to determine the diagnostic performance of the test and the threshold of significance was set at 0.05. Results: Of the 45 subjects recruited, 32 had heart failure and 13 had COPD. The NT-pro BNP levels were higher in HF patients (3725.5 [651 – 9945] pg/ml) compared to the COPD patients (316 [32- 1307] pg/ml); p=0.02. The NT-pro BNP levels was correlated to dyspnea in both groups (r=0.75; p<0.001 in HF patients and r=0.91; p<0,001 in COPD patients). The diagnostic threshold obtained was 497 pg/ml with a sensitivity of 81%, a specificity of 69% and a Youden’s index of 0.5. Conclusion: The diagnostic performance of NT-proBNP is acceptable in distinguishing between heart failure and COPD.

Diagnosis NT-proBNP dyspnea heart failure chronic obstructive pulmonary disease.

References (17)

  1. 1 COPD Guidelines: A Review of the 2018 GOLD Report [DOI]
  2. 2 The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting [DOI]
  3. 3 BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine [DOI]
  4. 4 Atrial and brain natriuretic peptides: Hormones secreted from the heart [DOI]
  5. 5 The Differential Diagnosis of Dyspnea [DOI]
  6. 6 Echocardiographic Assessment of Left Ventricular Systolic Function: An Overview of Contemporary Techniques, Including Speckle-Tracking Echocardiography [DOI]
  7. 7 Brain natriuretic peptide: Much more than a biomarker [DOI]
  8. 8 1 Chronic obstructive pulmonary disease (COPD) [DOI]
  9. 9 [ROC (receiver operating characteristics) curve: principles and application in biology].
  10. 10 Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study [DOI]
  11. 11 B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review [DOI]
  12. 12 Palliative care and prognosis in COPD: a systematic review with a validation cohort [DOI]
  13. 13 European Society of Cardiology Heart Failure Long-Term Registry (Esc-Hf-Lt): 1-Year Follow-Up Outcomes and Differences Across Regions [DOI]
  14. 14 Causes and evaluation of chronic dyspnea.
  15. 15 NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort [DOI]
  16. 16 Plasma N-terminal Pro-brain Natriuretic Peptide: A Prognostic Marker in Patients with Chronic Obstructive Pulmonary Disease [DOI]
  17. 17 Diagnostic utility of b-type natriuretic peptide in patients with acute dyspnea or pleural effusions [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

63

Page views

0

PDF downloads

7

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.